We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services

Read time: Less than a minute

“We’ve learned that no other suppliers have exactly our expertise in this area. We felt discontinuing this service left our customers with no viable option for highly modified radioactive oligonucleotides, and therefore we had to rescind our decision,” said TriLink CEO, Dr. Richard Hogrefe.

TriLink leads the industry in unique modified nucleic acids and mid-scale oligonucleotide synthesis. High quality products and technical support are its key strengths. TriLink operates a fully GMP laboratory with a QSR environment. TriLink has over 13 years experience synthesizing radiolabeled DNA and RNA oligonucleotides. 35S and 3H labeling of both phosphodiester and phosphorothioate oligonucleotides are offered, as well as additional modifications.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.